ArticleJournal of gastrointestinal cancer2026
Clinical Outcomes of Second-Line FOLFIRI Plus Ramucirumab According to Prior Biologic Exposure in Metastatic Colorectal Cancer: A Retrospective Comparison of Prior Bevacizumab and Prior Anti-EGFR Cohorts.
Tamotsu Sagawa et al.PubMed ↗Publisher ↗
No numbers read from the abstract.